Northwest Biotherapeutics (LTS:0K95) Total Stockholders Equity : £-57.67 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Northwest Biotherapeutics Total Stockholders Equity?

Northwest Biotherapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was £-57.67 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Northwest Biotherapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was £-0.05. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Northwest Biotherapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was -0.67.

Northwest Biotherapeutics Total Stockholders Equity Historical Data

The historical data trend for Northwest Biotherapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Total Stockholders Equity Chart

Northwest Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

-34.38

-270.03

-93.24

-105.17

-51.96

Northwest Biotherapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															-46.13	-48.34	-52.62	-51.96	-57.67

Northwest Biotherapeutics (LTS:0K95) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Northwest Biotherapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-57.673	-	0)	/	1195.36
	=	-0.05

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Northwest Biotherapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(27.134	+	11.489)	/	-57.673
	=	-0.67

Northwest Biotherapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Northwest Biotherapeutics (LTS:0K95) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

NWBO:USA NBYB:Germany

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics (LTS:0K95) Headlines

No Headlines